Jph.Pl

JPH.PL maintains a strong liquidity position, with a current ratio of 3.41 and $12.2 million in cash and equivalents, indicating the company can easily cover its short-term obligations. The debt-to-equity ratio of 0.02 suggests a conservative capital structure, with minimal reliance on debt financing. Free cash flow of $8.9 million supports operational flexibility and potential reinvestment opportunities.

Profitability metrics show JPH.PL outperforms the industry median in return on equity (ROE) at 11.69% and return on assets (ROA) at 8.89%. These figures suggest efficient use of equity and asset base to generate returns. Gross profit of $27.5 million and operating income of $13.1 million reflect strong cost control and pricing power in its core markets.

Geographically, JPH.PL's revenue concentration is not disclosed in the available data, but its business model is likely diversified across multiple markets given the global nature of the pharmaceutical industry. No specific segment breakdown is provided in the input data.

Looking ahead, JPH.PL is projected to maintain a stable growth trajectory, with no significant revenue deltas expected in the current or next fiscal year. The company's capital expenditure of -$2.1 million indicates a reduction in investment in physical assets, which may reflect a shift toward cost optimization or a mature product lifecycle.

Risk factors for JPH.PL are currently low, with no immediate liquidity or dilution concerns identified. The company's low debt load and strong cash position reduce financial risk exposure. Additionally, no dilution sources were identified in the available filings or transcripts.

Recent filings and transcripts do not highlight any material events or strategic shifts for JPH.PL. The company appears to be operating within a stable regulatory and market environment, with no disclosed near-term disruptions.